Knight Therapeutics (TSX:GUD) YoY EBITDA Growth : 333.33% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Knight Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 333.33%.

Knight Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was C$0.24.

Knight Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Knight Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics YoY EBITDA Growth Chart

Knight Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

161.22

-8.59

-52.99

73.18

66.67

Knight Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial															-1,600.00	-19.39	13.48	-33.76	333.33

Knight Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Knight Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(0.635	-	0.381)	/	\| 0.381 \|
=	66.67 %

Knight Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(0.238	-	-0.102)	/	\| -0.102 \|
=	333.33 %

Knight Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

KHTRF:USA 04K:Germany

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Janice Jean Murray	Director
Nicolas Sujoy	Director
Long Zone Holdings Inc.	10% Security Holder
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines